Performance

Exelixis, Inc. (EXEL)

The first biotech stock we tackled was EXEL recommending a short sale on Jan 24th and then again on Feb 7th

Click on the image to zoom

After calling two important tops in EXEL within a period of two weeks, the stock subsequently declined “as predicted” to the rising 1X2 angle where we recommended covering the short within a day and $0.50 of the exact low and going long (see graph below).

Click on the image to zoom

Over the next eighteen days the stock moved up into first resistance at the $25 level where we recommended taking profits of $3.77 or 17.8% in just three weeks.

Click on the image to zoom

For those who elected to short the stock “into strong resistance at the $25-26 level” they got another opportunity to take profits and go long on March 27th at virtually the exact low at the $23 level with an extremely tight stop risking just $0.25 per share.

Click on the image to zoom

Had one followed our recommendations on EXEL (explicit and implied) over the period 1/24/19 to 3/29/19 they could have taken out profits over $8 or 34% (shorts=$4.37 and longs=$3.77)